Researchers in South Korea have proposed a novel cancer immunotherapy approach that could complement existing CAR-T (Chimeric Antigen Receptor T-cell) treatments.

CAR T-cell therapy is a type of adoptive cell transfer that involves genetically modifying a patient's T-cell lymphocytes to become CAR T-cells. Grown and multiplied in the laboratory, these cells ...

NOVEL lymph-node-inspired hydrogels enhance CAR T cell activation and proliferation by 50%, offering a more efficient and ...

1 This molecular program gives T cells the ability to remember threats that they’ve seen before and mount an immune response for a long period of time—key assets for a CAR T cell training to fight a ...

Fighting cancer is exhausting for T cells. Hostile tumor microenvironments can drain their mitochondrial activity, leading to a condition known as T cell ... T cells for adoptive transfer.

Chimeric antigen receptor (CAR) T cell therapy is an immunotherapy. It uses a patient’s own immune system to fight certain blood cancers. Normal T cells can “hook” onto cancer cells and kill them, but ...

However, functional analysis and in vivo transfer of MHC multimer-stained cells is hampered by the persistence of T-cell receptor (TCR)–MHC interactions and subsequently induced signaling events.

Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of refractory or relapsed leukemia and hematologic malignancies, particularly over the past decade. Despite its ...